Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group.; Royal Free Hospital Clinic Cohort.; INSIGHT study group.; SMART study group.; ESPRIT study group..

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar.

2.

Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups.; SILCAAT Scientific Committee..

J Am Heart Assoc. 2014 May 28;3(3):e000844. doi: 10.1161/JAHA.114.000844.

3.

Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.

Lagler H, Grabmeier-Pfistershammer K, Touzeau-Römer V, Tobudic S, Ramharter M, Wenisch J, Gualdoni GA, Redlberger-Fritz M, Popow-Kraupp T, Rieger A, Burgmann H.

PLoS One. 2012;7(5):e36773. doi: 10.1371/journal.pone.0036773. Epub 2012 May 21.

4.

Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT).

Pett SL, Carey C, Lin E, Wentworth D, Lazovski J, Miró JM, Gordin F, Angus B, Rodriguez-Barradas M, Rubio R, Tambussi G, Cooper DA, Emery S; INSIGHT-ESPRIT Study Group..

HIV Med. 2011 Apr;12(4):219-27. doi: 10.1111/j.1468-1293.2010.00875.x. Epub 2010 Aug 31.

5.

Interleukin-2 therapy in patients with HIV infection.

INSIGHT-ESPRIT Study Group.; SILCAAT Scientific Committee., Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D.

N Engl J Med. 2009 Oct 15;361(16):1548-59. doi: 10.1056/NEJMoa0903175.

6.

The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).

Schindler K, Rieger A, Tura A, Gmeinhardt B, Touzeau-Römer V, Haider D, Pacini G, Ludvik B.

Horm Metab Res. 2009 Jul;41(7):573-9. doi: 10.1055/s-0029-1202779. Epub 2009 Mar 25.

PMID:
19322744

Supplemental Content

Loading ...
Support Center